Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey
Background. The introduction of carbidopa-levodopa extended-release (CD-LD ER) capsules (Rytary®) did not go as smoothly as expected, largely due to difficulty around dose conversion from available immediate-release (IR) levodopa (LD) formulations. The dose conversion table in the CD-LD ER prescribi...
Main Authors: | Robert A. Hauser, Ghazal Banisadr, Kara Vuong, David Freilich, Stanley Fisher, Richard D’Souza |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2021/6638088 |
Similar Items
-
Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
by: Jason Margolesky, et al.
Published: (2018-01-01) -
Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
by: Hauser RA, et al.
Published: (2018-03-01) -
Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson’s Disease with Motor Fluctuations
by: John C. Morgan, et al.
Published: (2018-01-01) -
Membranous nephropathy associated with the use of levodopa-carbidopa combination
by: V Chaitanya, et al.
Published: (2015-01-01) -
Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication
by: Nirosen Vijiaratnam, et al.
Published: (2017-09-01)